非奈利酮用于近期心衰恶化事件患者:FINEARTS-HF 试验
FINEARTS-HF 是一项随机双盲安慰剂对照试验,纳入左室射血分数≥40%的心衰患者,评估非奈利酮在近期心衰恶化事件不同时间窗内的疗效与安全性。预设分析显示,近期心衰恶化患者主要复合终点风险更高,非奈利酮在近期恶化者中可能带来更大绝对获益,但治疗与时间交互作用未达统计学显著(P=0.07)。
要点
- 近期心衰恶化(7天内或7天至3个月)患者主要复合终点风险显著高于无近期恶化者。
- 非奈利酮在近期心衰恶化患者中可能降低主要复合终点风险,绝对获益更明显。
- 近期心衰恶化患者使用非奈利酮未增加高钾血症和肾功能恶化风险。
核心结论
- 左室射血分数≥40%的心衰患者中,近期发生心衰恶化事件者复发心衰事件和心血管死亡风险更高。
- 非奈利酮在近期心衰恶化患者中可能带来增强的绝对治疗获益,但需未来研究进一步确认。
研究设计与样本
- FINEARTS-HF 为随机、双盲、安慰剂对照试验,纳入左室射血分数≥40%的心衰患者。
- 共 6001 例有效随机分配至非奈利酮或安慰剂,按心衰恶化事件距随机化时间进行预设分析。
主要发现
- 1219 例(20.3%)在恶化期间(749 例,12.5%)或 7 天内(470 例,7.8%)入组,2028 例(33.8%)在 7 天至 3 个月内入组,937 例(15.6%)在 3 个月后入组,1817 例(30.3%)无既往心衰恶化史。
- 主要复合终点发生率随距心衰恶化时间延长而降低,恶化期间或 7 天内入组者风险是 3 个月后或无既往恶化者的 2 倍以上(RR:2.13;95%CI:1.82-2.55)。
- 与安慰剂相比,非奈利酮在 7 天内入组者(RR:0.74;95%CI:0.57-0.95)和 7 天至 3 个月入组者(RR:0.79;95%CI:0.64-0.97)中主要复合终点风险降低幅度大于 3 个月后或无既往恶化者(RR:0.99;95%CI:0.81-1.21),但治疗与时间交互作用未确认(P=0.07)。
- 近期心衰恶化者中非奈利酮的绝对风险降低更明显(Ptrend=0.011)。
- 近期心衰恶化患者使用非奈利酮未增加高钾血症和肾功能恶化等不良事件风险。
临床怎么用
- 对左室射血分数≥40%且近期发生心衰恶化事件的患者,可考虑使用非奈利酮以降低复发心衰事件和心血管死亡风险。
- 近期心衰恶化患者使用非奈利酮时,高钾血症和肾功能恶化风险未增加,但仍需常规监测。
局限性
- 治疗与时间交互作用未达统计学显著(P=0.07),近期心衰恶化患者的增强获益信号需未来研究进一步确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with heart failure (HF) and a recent worsening heart failure (WHF) event are known to be at high risk of recurrent hospitalization and death, regardless of ejection fraction. OBJECTIVES: This study examined the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone in relation to the recency of a WHF event. METHODS: FINEARTS-HF (FINerenone trial to investigate Efficacy and sAfety superioR to placebo in paTientS with Heart Failure) was a randomized, double-blind, placebo-controlled trial of finerenone in patients with HF and left ventricular ejection fraction ≥40%. In this prespecified analysis, we assessed the risk of cardiovascular (CV) events and response to finerenone vs placebo in relation to the time from WHF to randomization (during or within 7 days, 7 days to 3 months, >3 months, or no prior WHF). The primary outcome was a composite of total (first and recurrent) WHF events and CV death, analyzed using a proportional rates method. RESULTS: Of 6,001 patients validly randomized to finerenone or placebo, 1,219 (20.3%) were enrolled during (749 [12.5%]) or within 7 days (470 [7.8%]), 2,028 (33.8%) between 7 days and 3 months, and 937 (15.6%) >3 months from a WHF event; 1,817 (30.3%) had no prior history of WHF. Rates of the primary composite outcome varied inversely with time since WHF, with >2-fold higher risk in those enrolled during or within 7 days of WHF compared with those enrolled >3 months from WHF or without prior WHF (risk ratio [RR]: 2.13; 95% CI: 1.82-2.55). Compared to placebo, finerenone appeared to lower the risk of the primary composite to a greater extent in those enrolled within 7 days of WHF (RR: 0.74; 95% CI: 0.57-0.95) or between 7 days and 3 months of WHF (RR: 0.79; 95% CI: 0.64-0.97) than in those >3 months from WHF or without prior WHF (RR: 0.99; 95% CI: 0.81-1.21); however, no definitive treatment-by-time interaction could be confirmed (P = 0.07). Greater absolute risk reductions with finerenone were accordingly seen in those with recent WHF (Ptrend = 0.011). The risk of adverse events including hyperkalemia and worsening renal function among patients assigned to finerenone was not increased in those with recent WHF. CONCLUSIONS: Compared with those without recent WHF, patients with HF and mildly reduced or preserved ejection fraction who have experienced a recent WHF event are at higher risk for recurrent HF events and CV death; a possible signal of enhanced absolute treatment benefit with finerenone in this population requires further confirmation in future studies. (Study to Evaluate the Efficacy [Effect on Disease] and Safety of Finerenone on Morbidity [Events Indicating Disease Worsening] & Mortality [Death Rate] in Participants With Heart Failure and Left Ventricular Ejection Fraction [Proportion of Blood Expelled Per Heart Stroke] Greater or Equal to 40% [FINEARTS-HF], NCT04435626; A study to gather information on the influence of study drug finerenone on the number of deaths and hospitalizations in participants with heart failure EudraCT 2020-000306-29).
引用
- Desai, Vaduganathan, Claggett, et al. Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial. J Am Coll Cardiol. 2024. PMID: 39352340. doi:10.1016/j.jacc.2024.09.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。